雪榕生物
(300511)
| 流通市值：23.41亿 | | | 总市值：26.34亿 |
| 流通股本：5.70亿 | | | 总股本：6.41亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,698,639,640.68 | 1,156,300,523.07 | 678,923,162.65 | 1,987,614,708.05 |
| 营业收入 | 1,698,639,640.68 | 1,156,300,523.07 | 678,923,162.65 | 1,987,614,708.05 |
| 二、营业总成本 | 1,643,444,268.73 | 1,078,939,727.76 | 505,757,763.08 | 1,955,920,414.81 |
| 营业成本 | 1,467,927,307.7 | 956,854,384.73 | 450,581,731.92 | 1,716,846,513.77 |
| 税金及附加 | 15,124,248.95 | 10,075,850.07 | 5,147,487.72 | 20,532,645.44 |
| 销售费用 | 17,530,506.85 | 11,761,420.81 | 5,406,226.71 | 21,640,168.35 |
| 管理费用 | 101,307,972.02 | 69,344,278.45 | 28,647,149.88 | 136,942,903 |
| 研发费用 | 3,146,630.54 | 2,004,728.45 | 776,371.44 | 3,341,415.84 |
| 财务费用 | 38,407,602.67 | 28,899,065.25 | 15,198,795.41 | 56,616,768.41 |
| 其中:利息费用 | 27,042,485.18 | 19,164,702.83 | 9,423,249.14 | 60,684,635.89 |
| 其中:利息收入 | 377,925.43 | 338,472.96 | 196,432.26 | 646,799.72 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | 38,348.96 |
| 加:投资收益 | 978,869.63 | 961,913.61 | - | 1,013,061.49 |
| 资产处置收益 | 3,988,429.21 | 2,074,510.1 | 268,167.86 | 16,311,304.25 |
| 资产减值损失(新) | -114,244,570.37 | -70,888,706.45 | - | -16,196,762.52 |
| 信用减值损失(新) | -1,965,630.62 | -27,469.68 | 185,445.85 | -786,190.7 |
| 其他收益 | 7,912,497.39 | 4,978,289.05 | 2,331,194.11 | 10,578,024.07 |
| 四、营业利润 | -48,135,032.81 | 14,459,331.94 | 175,950,207.39 | 42,652,078.79 |
| 加:营业外收入 | 23,651.85 | 18,850.72 | 3,356.72 | 725,111.33 |
| 减:营业外支出 | 682,278.74 | 541,062.73 | 253,788.18 | 4,183,079.03 |
| 五、利润总额 | -48,793,659.7 | 13,937,119.93 | 175,699,775.93 | 39,194,111.09 |
| 减:所得税费用 | 229,886.85 | 211,754.96 | 48,312.57 | 775,374.64 |
| 六、净利润 | -49,023,546.55 | 13,725,364.97 | 175,651,463.36 | 38,418,736.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -49,023,546.55 | 13,725,364.97 | 175,651,463.36 | 38,418,736.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -47,392,482.5 | 17,854,930.15 | 173,170,360.14 | 29,793,998.17 |
| 少数股东损益 | -1,631,064.05 | -4,129,565.18 | 2,481,103.22 | 8,624,738.28 |
| 扣除非经常损益后的净利润 | -59,870,127.89 | 10,066,484.54 | 170,949,185.49 | 5,178,594.18 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.07 | 0.03 | 0.27 | 0.05 |
| (二)稀释每股收益 | -0.07 | 0.03 | 0.27 | 0.05 |
| 八、其他综合收益 | -4,374,845.2 | -3,308,407.86 | -2,155,034.21 | 1,062,270.97 |
| 归属于母公司股东的其他综合收益 | -2,633,603.33 | -1,969,532.73 | -1,297,302.32 | 615,589.41 |
| 九、综合收益总额 | -53,398,391.75 | 10,416,957.11 | 173,496,429.15 | 39,481,007.42 |
| 归属于母公司股东的综合收益总额 | -50,026,085.83 | 15,885,397.42 | 171,873,057.82 | 30,409,587.58 |
| 归属于少数股东的综合收益总额 | -3,372,305.92 | -5,468,440.31 | 1,623,371.33 | 9,071,419.84 |
| 公告日期 | 2026-10-27 | 2026-08-25 | 2026-04-28 | 2026-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |